Swedish Orphan Biovitrum AB (publ) (STO:SOBI)

Market Cap	91.11B
Revenue (ttm)	26.97B
Net Income (ttm)	4.37B
Shares Out	344.61M
EPS (ttm)	12.60
PE Ratio	20.98
Forward PE	16.05
Dividend	n/a
Ex-Dividend Date	n/a

Volume	355,860
Average Volume	264,653
Open	265.40
Previous Close	269.60
Day's Range	261.20 - 266.00
52-Week Range	241.80 - 354.40
Beta	0.23
RSI	39.11
Earnings Date	Jul 16, 2025

About CrossFirst Bankshares

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocy...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1939
• Employees: 1,806
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SOBI

Financial Performance

In 2024, STO:SOBI's revenue was 26.03 billion, an increase of 17.65% compared to the previous year's 22.12 billion. Earnings were 3.89 billion, an increase of 61.27%.